COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase I/II Study of Sunitinib and Dacarbazine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00496223
Recruitment Status : Terminated (toxicities required dose reduction compromising effectiveness and PI left Moffitt)
First Posted : July 4, 2007
Last Update Posted : February 23, 2011
Information provided by:
H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : June 2007
Actual Study Completion Date : June 2007